BKV (NYSE:BKV - Get Free Report) had its price target lifted by analysts at Barclays from $29.00 to $30.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Barclays's target price would suggest a potential upside of 34.87% from the company's current price.
Other equities analysts have also recently issued reports about the stock. Evercore ISI upped their price objective on shares of BKV from $20.00 to $26.00 and gave the stock an "outperform" rating in a research report on Friday, May 30th. Truist Financial dropped their price objective on shares of BKV from $31.00 to $30.00 and set a "buy" rating on the stock in a report on Monday, March 17th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $28.25.
Check Out Our Latest Analysis on BKV
BKV Price Performance
NYSE:BKV traded down $0.51 during trading hours on Monday, reaching $22.24. The company's stock had a trading volume of 196,649 shares, compared to its average volume of 448,226. The company has a current ratio of 0.41, a quick ratio of 0.39 and a debt-to-equity ratio of 0.13. BKV has a one year low of $15.00 and a one year high of $26.78. The business's 50-day moving average is $21.93 and its 200-day moving average is $21.69.
BKV (NYSE:BKV - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.26. The company had revenue of $216.13 million for the quarter, compared to analyst estimates of $223.20 million. Research analysts anticipate that BKV will post -1.82 EPS for the current year.
Insider Activity
In other BKV news, CFO David Tameron sold 4,409 shares of BKV stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $17.94, for a total value of $79,097.46. Following the transaction, the chief financial officer directly owned 43,370 shares of the company's stock, valued at $778,057.80. The trade was a 9.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Eric S. Jacobsen sold 31,350 shares of BKV stock in a transaction on Monday, May 19th. The stock was sold at an average price of $22.02, for a total value of $690,327.00. Following the sale, the insider directly owned 257,903 shares of the company's stock, valued at approximately $5,679,024.06. This trade represents a 10.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 217,208 shares of company stock worth $4,695,833. 4.11% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On BKV
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System bought a new position in BKV in the fourth quarter valued at about $26,000. Corebridge Financial Inc. bought a new stake in BKV during the 4th quarter valued at $170,000. Bank of New York Mellon Corp purchased a new stake in shares of BKV in the fourth quarter worth $695,000. Quantbot Technologies LP bought a new stake in BKV during the first quarter worth about $1,605,000. Finally, Geode Capital Management LLC purchased a new stake in BKV during the 4th quarter valued at about $7,728,000.
BKV Company Profile
(
Get Free Report)
BKV Corporation engages in the acquisition, operation, and development of natural gas and NGL properties. It is also involved in the gathering, processing, and transportation of natural gas. The company was founded in 2015 and is based in Denver, Colorado with additional offices in Tunkhannock, Pennsylvania and Fort Worth, Texas.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BKV, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BKV wasn't on the list.
While BKV currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
